<DOC>
	<DOCNO>NCT00004124</DOCNO>
	<brief_summary>RATIONALE : Hormones stimulate production prostate cancer cell . Hormone therapy may fight prostate cancer reduce production androgen . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . It yet know whether hormone therapy plus mitoxantrone prednisone effective hormone therapy alone prostate cancer . PURPOSE : This randomized phase III trial study hormone therapy , mitoxantrone , prednisone see well work compare hormone therapy alone treat patient undergone radical prostatectomy prostate cancer .</brief_summary>
	<brief_title>S9921 , Hormone Therapy With Without Mitoxantrone Prednisone Patients Who Have Undergone Radical Prostatectomy Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare overall disease-free survival patient high-risk adenocarcinoma prostate treat adjuvant androgen deprivation therapy without mitoxantrone prednisone radical prostatectomy . - Compare qualitative quantitative toxic effect regimens patient population . - Compare prostate-specific antigen ( PSA ) progression-free survival rate patient treat regimen . - Determine whether PSA progression surrogate endpoint survival disease-free survival patient population . OUTLINE : This randomize , multicenter study . Patients stratify accord surgical extent disease ( organ confine vs organ confine , N0 v N1 ) , Gleason 's sum ( le 7 v 7 v great 7 ) , plan radiotherapy ( yes v ) . Patients randomize one two treatment arm . - Arm I : Patients receive goserelin subcutaneously every 13 week ( 8 injection total ) oral bicalutamide daily 2 year absence disease progression unacceptable toxicity . - Arm II : Patients receive mitoxantrone IV 30 minute day 1 oral prednisone twice daily day 1-21 . Treatment repeat every 3 week 6 course absence disease progression unacceptable toxicity . Patients also receive hormonal therapy arm I begin concurrently initiation mitoxantrone prednisone . Patients may undergo radiotherapy 5 day week 6.5-7.8 week begin anytime ( arm I ) completion chemotherapy ( arm II ) , discretion physician , absence disease progression unacceptable toxicity . Patients offer possibility participate biomarker research allow tissue/blood study . Patients follow every 6 month 2 year annually 13 year . PROJECTED ACCRUAL : A total 1,360 patient ( 680 per treatment arm ) accrue study within 9.5 year .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<mesh_term>Bicalutamide</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm stage T1T3 adenocarcinoma prostate radical prostatectomy lymph node dissection Must undergone prostatectomy within past 120 day Must meet least 1 follow pathologic criterion : Gleason sum least 8 pT3b ( seminal vesicle ) , pT4 , N1 Gleason sum 7 positive margin Preoperative PSA great 15 ng/mL , Gleason score great 7 , PSA level great 10 ng/mL Gleason score great 6 Must undetectable PSA ( great 0.2 ng/mL ) document surgery prior adjuvant hormonal therapy ( patient initiate adjuvant hormonal therapy prior study ) No evidence metastatic disease bone scan PSA 20 ng/mL great clinical diagnosis No distant metastatic disease PATIENT CHARACTERISTICS : Performance status : SWOG 01 Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify Cardiovascular : No uncontrolled congestive heart failure If history cardiac disease , LVEF least 50 % MUGA scan 2D echocardiogram Other : No HIV positivity No prior malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer stage I II cancer currently complete remission PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Not specify Endocrine therapy : Prior neoadjuvant hormonal therapy 4 month duration radical prostatectomy allow Other concurrent adjuvant hormonal therapy allow initiate prior study Concurrent lowdose megestrol ( le 40 mg/day ) hot flash allow Radiotherapy : No prior radiotherapy No concurrent whole pelvis irradiation Concurrent radiotherapy allow discretion physician Surgery : See Disease Characteristics See Endocrine therapy Recovered prior surgery Other : No prior concurrent therapy adenocarcinoma prostate</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>stage I prostate cancer</keyword>
	<keyword>stage II prostate cancer</keyword>
	<keyword>stage III prostate cancer</keyword>
</DOC>